Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

2024 High Conviction - New Horizon Health - Overhangs Are Over, Upgraded '23 Guidance

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Bottom-Up

<ul>
<li>New Horizon Health announced a positive profit alert yesterday after market close and held a conference call.</li>
<li>We participated in the call and spoke with the management to understand the recent developments.</li>
<li>The company upgraded '23 revenue guidance and provided revenue guidance for '24.</li>
</ul>


New Horizon Health announced a positive profit alert yesterday after market close and held a conference call.
We participated in the call and spoke with the management to understand the recent developments.
The company upgraded '23 revenue guidance and provided revenue guidance for '24.


New Horizon Health: Positive Alert, Upgrades '23 Revenue Guidance